LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin at -2182.4%
Net margin was -2182.4% in Q1 FY2026. On a trailing-twelve-month basis it was -519.3%. Over 3 fiscal years it narrowed by 358.2 pp.
What to watch
Whether net margin reaches the consensus estimate from 5 analysts of -785.7% for the fiscal year ending Dec 2026, down from -430.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2182.4%+78.0 pp QoQ
- Last fiscal yearDec 2025
- -430.3%— YoY
- LTMMar 2026
- -519.3%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | -1090.1 pp | — |
| 1 year | — | -355.5 pp | — |
| 3 years | -358.2 pp | +406.5 pp | +764.7 pp |
| 5 years | +445.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -430.3%
- Year-over-year change
- —
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -430.3% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -72.1% | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How LENZ compares with its peers on the latest reported figures
- LENZ's LTM Mar 2026 net margin of -519.3% is the 6th highest of the 7 companies compared; the peer median is -58.9%.
- Over three fiscal years its change of -358.2 pp compares with a peer median of +1113.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 84.0% | +1279.8 pp | -59.9 pp | |
| LTM Mar 2026 | -35.5% | +84.1 pp | +23762.2 pp | |
| LTM Jun 2026 | -37.1% | +53.1 pp | -95.3 pp | |
| FY2025 | -80.8% | -1028.4 pp | +1113.5 pp | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | -200.0% | -183.9 pp | +2432.2 pp |
| LTM Mar 2026 | -519.3% | — | -358.2 pp | |
| LTM Mar 2026 | -4917.6% | +334.9 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding LENZ) | -58.9% | +68.6 pp | +1113.5 pp | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.